The first Cardio-Oncology Program in South Texas
Advanced chemotherapy and radiation treatment have greatly enhanced cancer patient survival. And now, Methodist Healthcare's oncologists and cardiologists are working together to predict, monitor and manage the effect cancer treatments have on the heart. We are proud to be the first in South Texas to develop a Cardio-Oncology Program–right here in San Antonio.
To learn more about our Cardio-Oncology Program, call the Methodist Healthcare HealthLine at (210) 575-0355.
How does cardio-oncology benefit patients?
- Early cardiac testing and regular monitoring, to help prevent cardiac complications for patients being treated with anthracyclines, radiation or molecular targeted therapies.
- If patients with previous cancer problems need cancer treatment, our program allows for an early identification adjustment of cardiovascular therapy and closer monitoring to match the clinical course of each patient.
Enhancing cancer treatment with predictive cardiac monitoring
Our goal is to enhance cancer care, including the effectiveness of treatment, through predictive and preventive cardiac monitoring. The Cardio-Oncology Program at Methodist Healthcare uses cardiac monitoring for:
- Early detection of patients at risk for cardiotoxicity—a condition where damage to the heart has occurred as a result of chemotherapy or other medications
- Minimize cardiotoxicity while treatment eliminates cancer
- Early implementation of cardioprotective agents—protective agents that help prevent further damage to the heart
- Maximizing the effectiveness of chemotherapy treatment
- Assisting the oncology team with data help determine the best course of treatment
- Providing patients with ongoing cardiovascular care before, during and after treatment
Access to advanced testing technology
Our facilities are equipped with the latest, most advanced cardiac imaging, monitoring and testing technologies, including:
- State-of-the-art electrocardiograms (EKG or ECG)
- 3D echocardiography
- Tests for biomarkers—such as troponin 1 and natriuretic peptide
- Monitoring of the development of microRNA and intracellular/intramitochondrial biomarkers to facilitate detection of cardiotoxicity
- Regular screenings and treatments for new patients and long-term cancer survivors with cardiotoxicity and/or other complications not directly related to cancer therapy